Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6892 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Taiwan Bio Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Bio Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Taiwan Bio Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics (ROCO:6892) has a Buyback Yield % of -0.25 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Taiwan Bio Therapeutics and its competitors. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #160 out of 738 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Taiwan Bio Therapeutics' Buyback Yield % too high?
Taiwan Bio Therapeutics' current Buyback Yield % is -0.25. Based on the distribution chart, Taiwan Bio Therapeutics ranks #160 out of 738 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #160 out of 738 companies for Buyback Yield %. This places Taiwan Bio Therapeutics in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current Buyback Yield % is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.61, compared to a current price of NT$25.90 — trading 77.3% above its estimated fair value. The current Buyback Yield % is -0.25. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Buyback Yield % is -0.25 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$25.90 is trading 77.3% above its estimated GF Value™ of NT$14.61.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
Buyback Yield %: -0.25
GF Value™: NT$14.61 vs. price of NT$25.90 (77.3% above fair value)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score
Get the complete analysis for ROCO:6892
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
